Evidence map›Paper›PMID 31213412›Full record

ArticleClinical genitourinary cancer2019

Rapid Deep Responses With Nivolumab Plus Ipilimumab in Papillary Renal Cell Carcinoma With Sarcomatoid Dedifferentiation.

Gustavo Schvartsman, Andre P C D Carneiro, Renee Z Filippi, Priya Rao, Pavlos Msaouel

Abstract readCase Reports
In one paragraph

Article in Clinical genitourinary cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. 2024 CUA-KCRNC Expert Report: Management of non-clear cell renal cell carcinoma.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2024
    Article
  3. Renal Cell Carcinoma of Variant Histology: Biology and Therapies.Hematology/oncology clinics of North America · 2023
    Review
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Gustavo SchvartsmanHospital Israelita Albert Einstein, São Paulo, Brazil. Electronic address: Gustavo.schvartsman@einstein.br.
Andre P C D CarneiroHospital Israelita Albert Einstein, São Paulo, Brazil.
Renee Z FilippiHospital Israelita Albert Einstein, São Paulo, Brazil.
Priya RaoThe University of Texas MD Anderson Cancer Center, Houston, TX.
Pavlos MsaouelThe University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: pmsaouel@mdanderson.org.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Renal CellHumansIpilimumabKidney NeoplasmsMaleMiddle AgedNivolumabTreatment OutcomeIpilimumabNivolumabCheckpoint inhibitorsCTLA-4ImmunotherapyKidney cancerPD-1

Identifiers

PMID31213412
PMCPMC12291105

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.